Volume 32, No 6, Jun 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 6, June 2022: 589-592   |  Open Access

LETTERS TO THE EDITOR

Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo

Mengjiao Li^1,2,3,4,† , Zi-Wei Ye^5,† , Kaiming Tang^5,6,† , Liang Guo^1,2,3,4,† , Wenwen Bi^2,3,4 , Yuyuan Zhang⁷ , Yan-dong Tang⁷ , Guoguang Rong^8,9 , Mohamad Sawan^8,9 , Xin Yin⁷ , Ren Sun^2,3,4,10 , Shuofeng Yuan^5,6,* , Bobo Dang^2,3,4,*

¹Fudan University, Shanghai, China
²Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China
³Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China
⁴Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China
⁵Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
⁶State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
⁷State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China
⁸CenBRAIN Lab., School of Engineering, Westlake University, Hangzhou, Zhejiang, China
⁹CenBRAIN Lab., Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China
¹⁰School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
^†These authors contributed equally: Mengjiao Li, Zi-Wei Ye, Kaiming Tang, Liang Guo
Correspondence: Shuofeng Yuan(yuansf@hku.hk)Bobo Dang(dangbobo@westlake.edu.cn)

Dear Editor,

The outbreak of coronavirus disease 2019 (COVID-19) has resulted in a severe global pandemic that has lasted for more than two years.1 Several vaccines were developed at an unprecedented speed to protect billions of people.2 Many monoclonal antibodies have also been discovered, several of which are in the clinical stages.3 However, limited vaccine availability and vaccine hesitancy compromise the impact of vaccines. The continuous evolution of SARS-CoV-2 has also resulted in many variants that can escape immunity, reducing the effects of vaccines and antibodies.4 With more than 30 mutations in the spike protein, the Omicron variant escapes the majority of existing antibodies and extensively evades vaccine-induced immunity.5,6 Thus, therapeutics that are broadly effective against current and future emerging SARS-CoV-2 variants are still highly desirable.

https://doi.org/10.1038/s41422-022-00656-4

FULL TEXT | PDF

Browse 289